For this reason, preventive strategies begin by identifying patients at high risk of developing OHSS to individualise the ovarian stimulation protocol (gonadotropins dose, duration of FSH exposure, etc.). This evidence concerns the gene BRD2 and ovarian hyperstimulation syndrome.